Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • DKA’s $6.8 Billion Burden: The Clinical and Economic Impact

    Diabetic ketoacidosis (DKA) costs the U.S. $6.8 billion annually and puts thousands of lives at risk. Discover why this preventable problem continues, who’s most vulnerable, and how emerging technologies can bend the curve.

    Read more

  • Estate Planning Checklist

    Estate planning is a method for determining how to distribute your property during your life and at your death. William Blair published an organizer to help facilitate the process.

    Read more

  • MillerKnoll, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of MillerKnoll. Inc. (MLKN $22.54), a global collective of leading brands that designs, manufactures, and retails furniture, interiors, and related products for workplace, residential, healthcare, and education environments.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures